Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBOAT4 | Q96T53 | 4/20 | 1.00 |
| ▸ | NOS2 | P35228 | 9/20 | 0.75 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.75 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.75 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.74 |
| ▸ | USP7 | Q93009 | 2/20 | 0.74 |
| ▸ | USP2 | O75604 | 1/20 | 0.74 |
| ▸ | STAT3 | P40763 | 1/20 | 0.74 |
| ▸ | CCR6 | P51684 | 1/20 | 0.65 |
| ▸ | RORC | P51449 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19635897 | 1.00 | MBOAT4 (1.00) | MBOAT4NOS2KEAP1CYP3A4CYP2C19 | |
| SCHEMBL15469127 | 1.00 | MBOAT4 (1.00) | MBOAT4NOS2KEAP1CYP3A4CYP2C19 | |
| SCHEMBL7716045 | 1.00 | MBOAT4 (1.00) | MBOAT4NOS2KEAP1CYP3A4CYP2C19 | |
| SCHEMBL18682368 | 0.93 | MBOAT4 (0.88) | MBOAT4NOS2KEAP1CYP3A4CYP2C19 | |
| SCHEMBL18682396 | 0.93 | MBOAT4 (0.88) | MBOAT4NOS2KEAP1CYP3A4CYP2C19 | |
| SCHEMBL18682607 | 0.93 | MBOAT4 (0.88) | MBOAT4NOS2KEAP1CYP3A4CYP2C19 | |
| SCHEMBL18682612 | 0.93 | MBOAT4 (0.88) | MBOAT4NOS2KEAP1CYP3A4CYP2C19 | |
| SCHEMBL20983761 | 0.92 | MBOAT4 (0.85) | MBOAT4NOS2KEAP1CYP3A4CYP2C19 | |
| SCHEMBL21022372 | 0.92 | MBOAT4 (0.85) | MBOAT4NOS2KEAP1CYP3A4CYP2C19 | |
| SCHEMBL18682395 | 0.92 | MBOAT4 (0.85) | MBOAT4NOS2KEAP1CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11919838-B2 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 | Reata Pharmaceuticals Holdings, LLC (US) | 2024-03-05 | — | — | US | disclosed |
| US-11911395-B2 | Methods of treating obesity using antioxidant inflammation modulators | Reata Pharmaceuticals Holdings, LLC (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230285500-A1 | Compositions and Methods for Gene Therapy for Corneal Endothelium Disorders | THE SCHEPENS EYE RESEARCH INSTITUTE, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230255982-A1 | METHODS OF TREATING COVID-19 USING BARDOXOLONE METHYL OR ANALOGS THEREOF | Reata Pharmaceuticals Holdings, LLC (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230250130-A1 | C4-MODIFIED OLEANOLIC ACID DERIVATIVES FOR INHIBITION OF IL-17 AND OTHER USES | REATA PHARMACEUTICALS, INC. | 2023-08-10 | — | — | US | disclosed |
| US-11584775-B2 | C4-modified oleanolic acid derivatives for inhibition of IL-17 and other uses | REATA PHARMACEUTICALS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20220024862-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17 | REATA PHARMACEUTICALS, INC. (US) | 2022-01-27 | — | — | US | disclosed |
| US-20210161914-A1 | METHODS OF TREATING ALPORT SYNDROME USING BARDOXOLONE METHYL OR ANALOGS THEREOF | REATA PHARMACEUTICALS, INC. (US) | 2021-06-03 | — | — | US | disclosed |
| US-10953020-B2 | Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof | REATA PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-20200289607-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF CORNEAL ENDOTHELIUM DISORDERS | THE SCHEPENS EYE RESEARCH INSTITUTE, INC. | 2020-09-17 | — | — | US | disclosed |
| US-20140377235-A1 | METHODS FOR USING SYNTHETIC TRITERPENOIDS IN THE TREATMENT OF BONE OR CARTILAGE DISEASES OR CONDITIONS | TRUSTEES OF DARTMOUTH COLLEGE | 2014-12-25 | — | — | US | disclosed |
| WO-2013169740-A2 | SYNTHETIC TRITERPENOIDS AND METHODS FOR MODULATING STEM/PROGENITOR CELL GENE EXPRESSION | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2013-11-14 | — | — | WO | disclosed |
| US-20120220652-A1 | Synthetic Triterpenoids and Methods of Use in the Treatment of Disease | REATA PHARMACEUTICALS, INC. | 2012-08-30 | — | — | US | disclosed |
| US-20120214814-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO ACID AND OTHER MODIFICATIONS AT C-17 | REATA PHARMACEUTICALS, INC. | 2012-08-23 | — | — | US | disclosed |
| US-20120101149-A1 | Betulinic Acid Derivatives and Methods of Use Thereof | REATA PHARMACEUTICALS, INC. | 2012-04-26 | — | — | US | disclosed |
| US-8129429-B2 | Synthetic triterpenoids and methods of use in the treatment of disease | REATA PHARMACEUTICALS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-8124656-B2 | Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring | REATA PHARMACEUTICALS, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20110281955-A1 | METHODS OF TREATING OBESITY USING ANTIOXIDANT INFLAMMATION MODULATORS | REATA PHARMACEUTICALS (US) | 2011-11-17 | — | — | US | disclosed |
| US-20090326063-A1 | SYNTHETIC TRITERPENOIDS AND METHODS OF USE IN THE TREATMENT OF DISEASE | REATA PHARMACEUTICALS, INC. | 2009-12-31 | — | — | US | disclosed |
| WO-2009023845-A2 | COMBINATION THERAPY WITH SYNTHETIC TRITERPENOIDS AND GEMCITABINE | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11911395-B2 | Methods of treating obesity using antioxidant inflammation modulators | TXNRD2, HMOX1, GPX4 | MBOAT4 92/4885NOS2 83/4885KEAP1 60/4885 |
| US-20200289607-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF CORNEAL ENDOTHELIUM DISORDERS | FECH, KEAP1, NFE2L2 | MBOAT4 4178/4885NOS2 366/4885KEAP1 2/4885 |
| US-20140377235-A1 | METHODS FOR USING SYNTHETIC TRITERPENOIDS IN THE TREATMENT OF BONE OR CARTILAGE DISEASES OR CONDITIONS | BMP2, BMP4, BMP1 | MBOAT4 2029/4885NOS2 1085/4885KEAP1 1977/4885 |
| US-20090326063-A1 | SYNTHETIC TRITERPENOIDS AND METHODS OF USE IN THE TREATMENT OF DISEASE | LIPG, CYP27A1, CYP11B1 | MBOAT4 1458/4885NOS2 378/4885KEAP1 444/4885 |
| US-20120214814-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO ACID AND OTHER MODIFICATIONS AT C-17 | IL17A, ALOX15, ALOX12 | MBOAT4 364/4885NOS2 35/4885KEAP1 87/4885 |
| US-20230250130-A1 | C4-MODIFIED OLEANOLIC ACID DERIVATIVES FOR INHIBITION OF IL-17 AND OTHER USES | IL17A, IL23R, ALOX15 | MBOAT4 954/4885NOS2 622/4885KEAP1 506/4885 |
| US-11919838-B2 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 | IL17A, ALOX15, ALOX12 | MBOAT4 415/4885NOS2 41/4885KEAP1 59/4885 |
| US-20220024862-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17 | IL17A, ALOX15, ALOX12 | MBOAT4 415/4885NOS2 41/4885KEAP1 59/4885 |
| US-20120220652-A1 | Synthetic Triterpenoids and Methods of Use in the Treatment of Disease | LIPG, CYP27A1, CYP11B1 | MBOAT4 1458/4885NOS2 378/4885KEAP1 444/4885 |
| US-20210161914-A1 | METHODS OF TREATING ALPORT SYNDROME USING BARDOXOLONE METHYL OR ANALOGS THEREOF | HSD11B2, CYP21A2, HSD11B1 | MBOAT4 912/4885NOS2 3518/4885KEAP1 694/4885 |
| US-20230255982-A1 | METHODS OF TREATING COVID-19 USING BARDOXOLONE METHYL OR ANALOGS THEREOF | CYP17A1, HSD11B2, HSD11B1 | MBOAT4 619/4885NOS2 471/4885KEAP1 207/4885 |
| US-20110281955-A1 | METHODS OF TREATING OBESITY USING ANTIOXIDANT INFLAMMATION MODULATORS | TXNRD2, HMOX1, GPX4 | MBOAT4 92/4885NOS2 83/4885KEAP1 60/4885 |
| US-20120101149-A1 | Betulinic Acid Derivatives and Methods of Use Thereof | BET1, PGGT1B, CYP3A5 | MBOAT4 3063/4885NOS2 1733/4885KEAP1 307/4885 |
| US-11584775-B2 | C4-modified oleanolic acid derivatives for inhibition of IL-17 and other uses | IL17A, IL23R, ALOX15 | MBOAT4 1187/4885NOS2 785/4885KEAP1 515/4885 |
| US-20230285500-A1 | Compositions and Methods for Gene Therapy for Corneal Endothelium Disorders | KEAP1, NFE2L2, TFAM | MBOAT4 3834/4885NOS2 540/4885KEAP1 1/4885 |
| US-10953020-B2 | Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof | HSD11B2, CYP21A2, HSD11B1 | MBOAT4 912/4885NOS2 3518/4885KEAP1 694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.